Latest Episodes
37
Episode 37: Will Greene, Prader-Willi Syndrome patient advocate, Healthcare Engagement Lead at Roche
"The history of rare disease drug development indicates that once you start looking harder for cases, you often tend to find them." - Will...
36
Episode 36: Zak Kohane, Department of Biomedical Informatics at Harvard Medical School
"Patients have already been exposed to these large language models (LLMs). Yes, they are aware of the risks, but they are also very aware...
35
Episode 35: Charlene Son Rigby, CEO at Global Genes
"And what I was really surprised about was that everybody was doing data collection in a different way. And I kept thinking that, gosh,...
34
Episode 34: Dan Mandell, CEO at GRO Biosciences
"So we built the seatbelts before the car, so to speak, wherein we did a project to figure out ways to biocontain these organisms....
33
Episode 33: Diana Sims-Silbermann, Clinician and Former Senior Trial Manager at Janssen Pharmaceuticals
32
Episode 32: Stephanie Wisner, Author, Co-Founder at Centivax
"In research or in biotech, time is expensive. Time is the most expensive thing that you have." - Stephanie Wisner, Author, Co-Founder at Centivax...